婴儿HIV感染者联用利福平对阿巴卡韦和拉米夫定药代动力学的影响
结果显示利福平对阿巴卡韦和拉米夫定的暴露影响极小,无需调整剂量。
要点
- 利福平联用不显著改变婴儿阿巴卡韦和拉米夫定的AUC。
- 接受利福平治疗的婴儿无需调整阿巴卡韦/拉米夫定剂量。
- 研究样本量小,结果需更大规模研究验证。
核心结论
- 利福平联合治疗对婴儿阿巴卡韦和拉米夫定的药代动力学影响极小。
- 接受含利福平抗结核治疗时无需调整阿巴卡韦/拉米夫定剂量。
研究设计与样本
- 药代动力学亚研究,嵌套于EMPIRICAL试验(NCT03915366)。
- 5例仅接受抗逆转录病毒治疗,13例同时接受利福平为基础的抗结核治疗。
- 阿巴卡韦/拉米夫定剂量在利福平联用期间保持不变。
- 24小时内采集6个血浆浓度,采用非房室药代动力学分析。
主要发现
- 中位(IQR)年龄为6.8(5.2-10.2)个月,体重为6.0(5.3-6.8)kg,组间可比。
- 阿巴卡韦暴露在联用与未联用利福平时相当(AUC0-24h:21.9 vs 21.0 h·mg/L;Cmax:6.2 vs 6.3 mg/L)。
- 拉米夫定暴露也相当(AUC0-24h:12.6 vs 12.4 h·mg/L)。
- 利福平组Cmax略高(2.4 vs 1.9 mg/L),可能源于个体间变异或利福平抑制胃肠道转运体增加吸收,被认为无临床相关性。
临床怎么用
- 婴儿HIV感染者接受含利福平的抗结核治疗时,无需调整阿巴卡韦/拉米夫定剂量。
局限性
- 研究为观察性亚组分析,可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lamivudine and abacavir are key components of first-line paediatric antiretroviral therapy (ART). Rifampicin is part of drug-sensitive TB treatment in children. Rifampicin induces UDP-glucuronosyltransferases and renal transporters and inhibits gastrointestinal transporters involved in the pharmacokinetics of abacavir and lamivudine, but pharmacokinetic data on this potential interaction in infants are scarce. OBJECTIVE: To evaluate the effect of rifampicin on the pharmacokinetics of abacavir and lamivudine in infants aged 28-365 days and weighing >3 kg. METHODS: This pharmacokinetic sub-study was nested within the EMPIRICAL trial (NCT03915366). Eighteen infants from Mozambique, Uganda, Zambia and Zimbabwe received once-daily fixed-dose abacavir/lamivudine with dolutegravir according to WHO guidelines. Five infants received ART alone and 13 received ART plus rifampicin-based tuberculosis treatment. Abacavir/lamivudine dosing was unchanged during rifampicin co-treatment. Six plasma concentrations were measured over 24 h and analysed using non-compartmental pharmacokinetic analysis. RESULTS: Median (IQR) age and weight were 6.8 (5.2-10.2) months and 6.0 (5.3-6.8) kg, respectively, and were comparable between groups. Abacavir exposure was comparable with and without rifampicin (AUC0-24h: 21.9 versus 21.0 h mg/L; Cmax: 6.2 versus 6.3 mg/L, respectively). Lamivudine exposure was also comparable (AUC0-24h: 12.6 versus 12.4 h mg/LL, respectively). The slightly higher Cmax (2.4 versus 1.9 mg/L) in the rifampicin group is probably due to interindividual variability or increased absorption from rifampicin's inhibition of gastrointestinal drug transporters, and considered not clinically relevant. CONCLUSIONS: Rifampicin co-treatment had minimal impact on abacavir and lamivudine pharmacokinetics in infants. Dose adjustment of abacavir/lamivudine is not required during rifampicin-containing tuberculosis treatment.
引用
- Beca LSDAB, Mumbiro V, Bwakura M, et al. Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment. J Antimicrob Chemother. 2026. PMID: 42623117. doi:10.1093/jac/dkag281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。